A Mendelian randomized trial suggested that a targeted reduction in the PCSK9 concentration is significant for reducing the occurrence of AF (OR: 0.90, 95% CI: 0.83-0.97) and has a protective effect on patients at risk of AF 91. Here, PCSK9 is linked to atrial fibrillation.